Refana
  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates

3/10/2021

Industry Updates - Volume 6

0 Comments

Read Now
 
Picture
March has seen warnings of a 4th Wave, emergency use approval for a 1-shot vaccine and an increase in vaccine sales. Volume 6 looks at these headlines and more.
​
Global Pandemic
  • Global caseload up to almost 120 Million cases, 2.6 Million deaths
  • World Health Organization and CDC in U.S. issued warnings for a '4th Wave' of Covid-19 cases, triggered by more contagious COVID-19 variants from UK, South Africa, Brasil, elsewhere
  • However, the overall trend in new infections/deaths has been trending downwards in many countries for almost two months
  • U.S. situation is complex - 20+ states have seen increases in infections in recent weeks, even as a number of states - led by 2nd most populous state Texas (29 million people) - cancelled mask mandates and are opening up
  • Vaccination programs in two major countries - U.S. and the UK - have significant momentum 
    • U.S. now at 2+ million vaccinations/day; Biden administration projects there will be sufficient vaccines for everyone who wants to take them by May
    • 312 Million vaccinations world-wide
    • 2/3rds of all doses have been administered in U.S., UK, China, EU Countries
    • 100 countries still without any vaccinations
  • Israel reached vaccine doses administered of 7.5 Million, compared with its population aged 15 or older of 6.7 Million
    • Covid infections in the 50+ age group have fallen from 25% to 11% of new infections, while 47% are in the 19 or younger age group
    • Israel re-opening large venues (e.g., sports stadiums, concert halls) allowing access to Green digital passport holders which attest to full vaccination or antibodies from prior infection
    • Fears however as to the risks from the South African variant which has arrived; and the ‘R Rate’ still stubbornly close to 1, vs. 0.5-0.7 if the Pandemic is subsiding.

Industry
  • Johnsons & Johnson (J&J) one-shot vaccine was given EUA on 28 February
    • U.S. efficacy of 72% (but lower elsewhere, presumably due to new COVID-19 variants) compared to 94% for the mRNA competitors
    • Leading officials - including Dr, Fauci and the acting FDA Commissioner Janet Woodcock - stated that there is no real difference between these vaccines w.r.t. to serious outcomes
    • People should simply take whatever they can get
    • White House brokered deal between rivals Merck, J&J to increase production of J&J’s vaccine
  • Research shows that Pfizer vaccine produced 67% less antibodies against the South African variant; and Moderna produced 83% less antibodies
    • Implications for protection not clear; both companies are working on new vaccines (or booster shots for those previously inoculated) against South African variant
  • AstraZeneca expected to announce shortly that it has achieved enough events in its Stage 3 American trial to read data and make application to the FDA for EUA
  • The European Medicines Agency (EMA) has commenced a review of the Russian Sputnik V vaccine; officials cautioned that they have not received the data required on vaccinated people
    • Surveys in Russia found that 60% of Russians did not trust the Sputnik vaccine
  • The Chairman of Sinopharm - which has previously announced 79% efficacy for their WIV vaccine - said it was effective against new variants, including the South African variant
  • Reuters reported that Sinovac was effective against the Brazilian variant
  • Sinovac announced an updated efficacy rate from its Turkish trial of 83.5%
    • Mexico, Thailand, The Philippines, and Hong Kong have approved Sinovac’s WIV vaccine
    • Meanwhile, Ukraine fined local distributor of Sinovac for failing to deliver the vaccine on time
  • In India, Bharat announced Stage 3 results of its WIV vaccine, showing 81% efficacy
  • The WHO has granted EUA to Pfizer, Moderna, and AstraZeneca and will review next Sinopharm, Sinovac and J&J.

Financial news
  • Bharat sold 20 Million doses of its WIV vaccine to Brazil for U.S. $290 Million ($14.50/shot), even before it had its Stage 3 trial results
    • Mexico on the verge of approving Bharat’s vaccine
  • AstraZeneca sold its stake in Moderna for approx U.S. $1 Billion, but has not disclosed when this occurred; current market value of the stake would be close to U.S. $4 Billion
  • Moderna is forecasting Covid-19 vaccine sales of U.S. $18.4 Billion this year; compares with total sales revenue for all products at AstraZeneca last year of U.S. $26 Billion
  • Pfizer is projecting U.S. $15 Billion in Covid-19 vaccine sales this year
  • J&J expected COVID-19 vaccine sales this year: Up to U.S. $10 Billion
  • AstraZeneca expected COVID-19 sales this year: U.S. $6.4 Billion
  • Other players - Sinovac, Gamaleya, Novavax - all expecting U.S. $ Billions in sales
  • Average price points across existing suppliers: U.S. $20 - U.S. $40 for two-dose shots
  • G7 pledged U.S. $4.7 Billion to help finance global equitable access to tests, treatments and vaccines; compares with the U.S. $22 Billion estimated that is needed just to vaccinate the world's poorer countries.​
​
Back to Blog

Share

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

Details

    Categories

    All
    Industry
    Video

    Archives

    December 2022
    September 2022
    July 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020

    RSS Feed

​Practical Solutions for complex and ​urgent global medical problems

HOME     |     PROGRAMS    |    TEAM     |     ABOUT     |     NEWS
Privacy Policy | Cookie Policy
© 2023 Refana Inc
  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates